CARTITUDE-1 and LOCOMMOTION; Cilta-cel and standard of care in triple-class exposed multiple myeloma
In this study presented at EHA 2022, 1 the patient-reported outcomes of the phase II CARTITUDE-1 were compared to LocoMMotion, a prospective study of real-life standard of care in triple-class exposed patients with relapsed/refractory multiple myeloma treated with real-world clinical practice prior to March 2021.